Clinical trial
Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX…
NCT00439517 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00439517 |
|---|---|
| Title | Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. |
| Official title | A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab as First-line Therapy in Subjects With Metastatic Colorectal Cancer. |
| Acronym | FUTURE |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Previously Untreated Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | UFOX + Cetuximab, FOLFOX4 + Cetuximab |
| Enrollment | 302 |
| Start date | Feb 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | May 1, 2012 |
| First posted | Feb 23, 2007 |
| Last update posted | Jun 27, 2014 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, France, Germany, Greece, Hong Kong, Israel, Italy, Mexico and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: